Document:

<PAGE>   1
                                                                    EXHIBIT 4.20

                          SECURITIES PURCHASE AGREEMENT

         SECURITIES PURCHASE AGREEMENT (this "Agreement"), dated as of
          , 2000 between PerkinElmer, Inc., a Massachusetts corporation (the
"Purchaser"), and the undersigned equity holder (the "Holder") of Genomic
Solutions Inc., a Delaware corporation (the "Company").

                                    RECITALS

         WHEREAS, the Purchaser and the Company have entered into an Investment
Agreement dated as of December 14, 1999 (the "Investment Agreement"), a copy of
which the Company has delivered to the Holder, providing for the purchase by the
Purchaser of capital stock in the Company;

         WHEREAS, the Purchaser and the Company have entered into a Sales,
Marketing and Distribution Agreement, dated as of December 14, 1999 (the
"Distribution Agreement"), providing for the distribution by the Purchaser of
products of the Company;

         WHEREAS, the Purchaser and the Company wish to provide the Purchaser
with the option to acquire all of the outstanding equity securities of the
Company, and the Board of Directors of the Company has recommended that each
holder of the Company's equity securities execute an agreement in the form of
this Agreement (collectively, the "Securities Purchase Agreements");

         WHEREAS, a condition to the consummation of the transactions
contemplated by the Investment Agreement is the execution of Securities Purchase
Agreements by holders of capital stock, options or warrants of the Company who
hold in the aggregate no less than 85% of the outstanding shares of the
Company's common stock, $.001 par value per share (the "Common Stock"), assuming
the full conversion into, exercise for and exchange for Common Stock of all of
the Company's securities convertible into, exercisable for or exchangeable for
Common Stock; and

         WHEREAS, the Holder desires to grant to the Purchaser an irrevocable
option to purchase all of the equity securities of the Company, including
capital stock, convertible securities, options and warrants (collectively, the
"Equity Securities") owned by the Holder (such Equity Securities owned by the
Holder are hereinafter referred to as "Holder Securities") in order to induce
the Purchaser to consummate the transactions contemplated by the Investment
Agreement.

                                      -1-
<PAGE>   2

         NOW, THEREFORE, in consideration of these premises and good and
valuable consideration, the receipt and sufficiency of which is hereby
acknowledged, the parties hereto agree as follows:

         1. Grant of Option. Upon the terms and subject to the conditions herein
set forth, the Holder hereby grants the Purchaser an irrevocable option (the
"Option") to purchase all of the Holder Securities, free and clear of all liens,
claims, pledges, charges, restrictions, equities, options, voting rights and
encumbrances of any nature whatsoever (collectively, "Encumbrances"). The Option
may be exercised only if the Purchaser concurrently gives an exercise notice
pursuant to Section 2 of each of the Securities Purchase Agreements executed by
other holders of Equity Securities.

         2. Exercise of Option.

            (a) Subject to Section 2(b), the Option may be exercised at any time
and from time to time subsequent to the Effective Date until the Termination
Date (each as defined in Section 5), by written notice delivered to the Holder
as provided in Section 14 (the "Exercise Notice"). The closing of a purchase
specified in any Exercise Notice shall take place five business days after the
later of (i) the date the Exercise Notice is given or (ii) the expiration or
termination of all applicable waiting periods under the Hart-Scott-Rodino
Antitrust Improvements Act of 1976, as amended (the "HSR Act"). At the closing,
the Purchaser shall send to the Holder by a reputable nationwide overnight
courier service a check in the amount of the consideration payable for the
Holder Securities being purchased from the Holder, and the Purchaser shall take
all such actions necessary to effect the assignment to the Purchaser of the
Holder Securities being purchased and the vesting in the Purchaser of good and
marketable title thereto. The Purchaser shall thereafter be treated for all
purposes as the owner of such Holder Securities. Without limiting the foregoing,
the Purchaser is hereby authorized (x) to deliver Transfer Instruments (as
defined in Section 5) to the Company or its transfer agent to effect the
assignment of such Holder Securities to the Purchaser and (y) to require the
Company or its transfer agent to register the Purchaser as the record owner of
such Holder Securities.

            (b) The Purchaser may exercise the Option at any time on the
Effective Date by delivering an Exercise Notice to the Company on the Effective
Date and subsequently promptly delivering an Exercise Notice to the Holder in
accordance with Section 14. If the Purchaser does not exercise the Option as
provided in the immediately preceding sentence, the Company shall be deemed to
have given notice to the Purchaser (an "IPO Notice") on the day after the
Effective Date that it intends to file a registration statement with the
Securities and Exchange Commission relating to an initial public offering of
Common Stock (or callable common stock) (the "Registration Statement") firmly
underwritten by a nationally recognized underwriter who certifies to the
Purchaser that such underwriter believes that (i) the offering will result in no
less than $20,000,000 of gross proceeds to the Company and (ii) the securities
offered will qualify for listing on the New York Stock Exchange or the National
Market Tier of the Nasdaq Stock Market (an initial public offering that in fact
results in no less than $20,000,000 of gross proceeds to the Company and the
listing of the offered securities on the New York Stock Exchange or the National
Market Tier of the Nasdaq Stock Market is hereinafter referred to as a
"Qualified IPO"). Following the filing of an IPO Notice, the

                                      -2-
<PAGE>   3

Purchaser shall not have the right to exercise the Option until the expiration
of the 180-day period following consummation of the initial public offering;
provided, however, that the Purchaser shall have the right to exercise the
Option at any time after (x) withdrawal or abandonment of the Registration
Statement by the Company or (y) consummation of an initial public offering that
is not a Qualified IPO. The Company may at any time notify the Purchaser that it
is revoking an IPO Notice, in which event the Purchaser shall have the right to
exercise the Option at any time after the notice of revocation is given. If the
Company revokes an IPO Notice, it may subsequently give one or more additional
IPO Notices, in each instance upon no less than 30 days' prior notice to the
Purchaser. In no event shall the Purchaser be prohibited from exercising the
Option for an aggregate number of days exceeding 270 days.

         3. Purchase Price.

            (a) Upon the closing of a purchase of Holder Securities following
the exercise of the Option, the Purchaser shall pay the Holder the purchase
price set forth in this Section 3. The purchase price shall be calculated based
on the number of days that have elapsed between the Effective Date and the date
on which the Exercise Notice is given, as set forth in the table below. The
purchase price (the "Option Price") for Holder Securities that are Common Stock
(subject to adjustment for stock splits, recapitalization, reclassifications or
similar events) shall be as set forth below:
<TABLE>
<CAPTION>

        ------------------------------- ----------------------------------------
                                                Number of Days that have
             Price Per Share of              Elapsed between the Effective
             Common Stock                    Date and the Date the Exercise
                                                    Notice is Given
<S>                                     <C>
        ------------------------------- ----------------------------------------
                    $6.75                             1 through 182
        ------------------------------- ----------------------------------------
                    $7.00                            183 through 365
        ------------------------------- ----------------------------------------
                    $7.50                            366 through 548
        ------------------------------- ----------------------------------------
                    $8.00                            549 through 730
        ------------------------------- ----------------------------------------
</TABLE>

; provided, however, that no days during which the Purchaser is prohibited from
exercising the Option pursuant to Section 2(b) shall be included in calculating
the number of days that have elapsed between the Effective Date and the date of
giving of the Exercise Notice.

            (b) The purchase price payable for any Holder Securities that are
not Common Stock shall be calculated on the basis of the number of shares of
Common Stock into or for which the Holder Security is convertible, exercisable
or exchangeable, net of any conversion, exercise or exchange price that would be
payable by the Holder upon such conversion, exercise or exchange.
Notwithstanding the foregoing, in lieu of paying cash for Holder Securities that
are employee stock options, the Purchaser may assume such stock options and
substitute therefor the option to acquire, on the same terms and conditions,
such number of shares of common stock of the Purchaser as is equal to the number
of shares of Common Stock subject to the unexercised portion of such option
multiplied by the Conversion Ratio (as defined below), with any fraction
resulting from such multiplication to be rounded down to the nearest whole
number. The exercise price per share of each such assumed option shall be equal
to the exercise price of such

                                      -3-
<PAGE>   4

option immediately prior to the giving of the Exercise Notice divided by the
Conversion Ratio, rounded up to the nearest whole cent. The term,
exercisability, vesting schedule and all of the other terms of the stock option
shall remain unchanged. "Conversion Ratio" shall mean the purchase price per
share of Common Stock calculated pursuant to Section 3(a), divided by the
average of the last reported sale prices per share, over the 30 trading days
ending on the trading day prior to the day the Exercise Notice is given, of the
Purchaser's common stock, as reported on the New York Stock Exchange.

            (c) The Option Prices set forth in Section 3(a) shall be subject to
adjustment from time to time as follows:

               (i) If the Company shall at any time or from time to time issue
            any shares of Common Stock, or securities convertible into or
            exercisable for Common Stock (including any shares of Common Stock
            deemed to have been issued pursuant to subdivision (iv)(c) below)
            other than Excluded Stock (as defined in clause (v) below) without
            consideration or for a consideration per share less than the Option
            Price in effect immediately prior to the issuance of such Common
            Stock, then any Option Price that is greater than the consideration
            per share of Common Stock or its equivalent received in such
            issuance or sale shall forthwith be lowered to be equal to the
            quotient obtained by dividing:

                   (a) an amount equal to the sum of (x) the total number of
               shares of Common Stock outstanding (including any shares of
               Common Stock deemed to have been issued pursuant to subdivision
               (iv)(c) below and any additional shares that would be issued as a
               result of giving effect to any anti-dilution provisions that are
               triggered by the issuance in question) immediately prior to such
               issuance, multiplied by the applicable Option Price in effect
               immediately prior to such issuance, and (y) the consideration
               received by the corporation upon such issuance (other than any
               consideration received from the Purchaser); by

                   (b) the total number of shares of Common Stock outstanding
               (including any shares of Common Stock deemed to have been issued
               pursuant to subdivision (iv)(c) below and any additional shares
               that would be issued as a result of giving effect to any
               anti-dilution provisions that are triggered by the issuance in
               question) immediately after the issuance of such Common Stock
               (excluding any shares of such Common Stock purchased by the
               Purchaser).

            For the purposes of any adjustment of any Option Price pursuant to
            this clause, the following provisions shall be applicable:

               (ii) In the case of the issuance of Common Stock for cash,
            the consideration shall be deemed to be the amount of cash paid
            therefor after deducting therefrom any discounts, commissions or
            other expenses allowed, paid or incurred by the corporation for
            any underwriting or otherwise in connection

                                      -4-
<PAGE>   5

            with the issuance and sale thereof.

                           (iii) In the case of the issuance of Common Stock for
            a consideration in whole or in part other than cash, the
            consideration other than cash shall be deemed to be the fair market
            value thereof as determined in good faith by the Company's Board of
            Directors, irrespective of any accounting treatment.

                           (iv) In the case of the issuance of options to
            purchase or rights to subscribe for Common Stock, securities by
            their terms convertible into or exchangeable for Common Stock, or
            options to purchase or rights to subscribe for such convertible or
            exchangeable securities:

                                    (a) the aggregate maximum number of shares
                           of Common Stock deliverable upon exercise of such
                           options to purchase or rights to subscribe for Common
                           Stock shall be deemed to have been issued at the time
                           such options or rights were issued and for a
                           consideration equal to the consideration (determined
                           in the manner provided in subdivisions (ii) and (iii)
                           above), if any, received by the Company upon the
                           issuance of such options or rights plus the minimum
                           purchase price provided in such options or rights for
                           the Common Stock covered thereby;

                                    (b) the aggregate maximum number of shares
                           of Common Stock deliverable upon conversion of or in
                           exchange for any such convertible or exchangeable
                           securities or upon the exercise of options to
                           purchase or rights to subscribe for such convertible
                           or exchangeable securities and subsequent conversion
                           or exchange thereof shall be deemed to have been
                           issued at the time such securities, options, or
                           rights were issued and for a consideration equal to
                           the consideration received by the Company for any
                           such securities and related options or rights
                           (excluding any cash received on account of accrued
                           interest or accrued dividends), plus the additional
                           consideration, if any, to be received by the Company
                           upon the conversion or exchange of such securities or
                           the exercise of any related options or rights (the
                           consideration in each case to be determined in the
                           manner provided in subdivisions (ii) and (iii)
                           above);

                                    (c) on any change in the number of shares or
                           exercise price of Common Stock deliverable upon
                           exercise of any such options or rights or conversions
                           of or exchange for such securities, including without
                           limitation a change resulting from the antidilution
                           provisions thereof, each Option Price previously
                           adjusted shall forthwith be readjusted to such Option
                           Price as would have been obtained had the adjustment
                           made upon the issuance of such options, rights or
                           securities not converted prior to such change or
                           options or rights related to such securities not
                           converted prior to such change been made upon the
                           basis of such change; and

                                    (d) on the expiration of any such options or
                           rights, the

                                      -5-
<PAGE>   6

                          termination of any such rights to convert or exchange
                          or the expiration of any options or rights related to
                          such convertible or exchangeable securities, each
                          Option Price previously adjusted shall forthwith be
                          readjusted to such Option Price as would have obtained
                          had the adjustment made upon the issuance of such
                          options, rights, securities or options or rights
                          related to such securities been made upon the basis of
                          the issuance of only the number of shares of Common
                          Stock actually issued upon the exercise of such
                          options or rights, upon the conversion or exchange of
                          such securities, or upon the exercise of the options
                          or rights related to such securities and subsequent
                          conversion or exchange thereof.

                          (v) "Excluded Stock" means (1) shares of Common Stock
                  issued by the Company as a stock dividend or upon any
                  subdivision, split-up or combination of shares of Common
                  Stock; (2) shares of Common Stock issued upon exercise of
                  incentive or non-qualified stock options outstanding as of the
                  date hereof; (3) shares of Common Stock issued upon exercise
                  of incentive or non-qualified options granted after the date
                  hereof in the ordinary course of business consistent with past
                  practice to employees, consultants or non-employee directors
                  pursuant to the existing stock option plans adopted by the
                  Board of Directors; (4) shares of Common Stock issued by the
                  Company upon conversion of shares of Preferred Stock; (5)
                  shares of Common Stock issued upon exercise of any warrants
                  issued to ESA, Inc., a Massachusetts corporation, pursuant to
                  the Warrant to Purchase Common Stock of Genomic Solutions Inc.
                  dated October 13 1998, (6) shares of Common Stock issued upon
                  exercise of any warrants issued pursuant to the terms of the
                  Business Loan Agreement between the Company, White Pines
                  Limited Partnership I and others dated April 23, 1999 (the
                  "April Loan Agreement"); (7) shares of Common Stock issued
                  upon exercise of any warrants issued pursuant to the terms of
                  the Business Loan Agreement between the Company, White Pines
                  Limited Partnership I and others dated October 28, 1999 (the
                  "October Loan Agreement", and, together with the April Loan
                  Agreement, the "Loan Agreements"); or (8) shares of Common
                  Stock issued to the Lenders (as defined in the Loan
                  Agreements) in partial payment of interest on the promissory
                  notes delivered to the Lenders under the Loan Agreements.

                          (vi) All adjustments to the Option Prices made
                  pursuant to this Section 3(c) shall be rounded to the nearest
                  cent.

         4. Delivery of Transfer Instruments. The Holder has delivered to the
Purchaser, or will deliver on or prior to the Effective Date, original stock
certificates, option agreements, warrants and other instruments evidencing the
ownership of the Holder Securities, with stock powers, in the case of capital
stock, and instruments of assignment, in the case of options and warrants,
attached and duly executed in blank (collectively, the "Transfer Instruments").
The Purchaser shall hold the Transfer Instruments pursuant to the terms of this
Agreement and use them only for the purposes set forth in this Agreement.

         5.       Termination.

                                      -6-
<PAGE>   7

                  (a) The "Effective Date" shall mean the Closing Date, as
defined in the Investment Agreement. The obligations of the Purchaser and the
Holder under this Agreement will terminate at 5:00 p.m., Boston time, on the
second anniversary of the Effective Date (the "Termination Date"); provided,
however, that the Termination Date shall be extended by the aggregate number of
days during which the Purchaser is prohibited from exercising the Option
pursuant to Section 2(b) hereof; provided, further, that if the Purchaser gives
the Exercise Notice prior to the Termination Date, this Agreement shall continue
in effect until the consummation of the purchase set forth in the Exercise
Notice. Promptly following the Termination Date, the Purchaser shall deliver to
the Holder all Transfer Instruments relating to Holder Securities for which no
Exercise Notice was given prior to the Termination Date.

                  (b) Notwithstanding the foregoing, if (i) the Company has
given the Purchaser an IPO Notice that has not been revoked, (ii) the Company
notifies the Purchaser that it has resolved all comments made by the staff of
the Securities and Exchange Commission relating to the proposed initial public
offering and is prepared to seek effectiveness of the Registration Statement and
(iii) simultaneously with or after the notice described in clause (ii) above,
the lead underwriter for the proposed initial public offering certifies to the
Purchaser that the offering will be a Qualified IPO, then the Termination Date
shall occur on the effective date of the reclassification of the equity
securities contemplated by Section 7.7(c) of the Investment Agreement pursuant
to which the Equity Securities are exchanged for similar securities of the
Company that are callable by the Company. Promptly following the Termination
Date described in this section 5(b), the Purchaser shall deliver all of the
Transfer Instruments it then holds to the Company.

                  (c) Promptly following the Termination Date, the Purchaser
shall file termination statements on Form UCC-3 with respect to all Holder
Securities for which no Exercise Notice has been given.

         6. Holder's Representations and Warranties. The Holder represents and
warrants to the Purchaser that as of the Effective Date:

                  (a) the Holder is the owner of, and has good and marketable
title to, the Holder Securities and the Holder Securities represent all the
capital stock of the Company, or securities convertible into, exercisable for or
exchangeable for capital stock of the Company, owned by the Holder, directly or
indirectly;

                  (b) except as set forth in the Stockholders Agreement, dated
as of December 24, 1997, among the Company and certain of its shareholders, as
amended, the Holder owns the Holder Securities free and clear of all
Encumbrances, except for the security interest granted herein;

                  (c) the Holder has the full and unrestricted legal power,
authority and right to enter into, execute, deliver and perform this Agreement;

                  (d) the Holder has the full and unrestricted legal power,
authority and right to sell, transfer and convey the Holder Securities to the
Purchaser as provided in this Agreement;

                                      -7-
<PAGE>   8

            (e) the Holder has duly executed and delivered this Agreement
and this Agreement constitutes a valid and binding agreement of the Holder
enforceable in accordance with its terms; and

            (f) neither the execution nor the delivery of this Agreement
by the Holder nor the consummation by the Holder of the transactions
contemplated hereby will (A) to the knowledge of the Holder, require the
consent, waiver, approval, license or authorization of, or any filings with any
person or public authority, other than any filings by the Purchaser under the
HSR Act, (B) with or without the giving of notice or lapse of time or both,
conflict with or constitute a violation of, or default on, or give rise to any
right of acceleration under any indenture, contract, commitment, agreement,
arrangement or other instrument of any kind to which the Holder is a party or by
which the Holder is bound, or (C) to the knowledge of the Holder, violate any
existing applicable law, rule, regulation, judgment, order or decree of any
governmental instrumentality or court having jurisdiction over the Holder.

         7. Holder's Covenants. The Holder covenants and agrees with the
Purchaser that:

            (a) any Equity Securities obtained by the Holder after the date
hereof, including without limitation any shares into or for which Equity
Securities are converted or exercised, shall be deemed to be "Holder Securities"
and thereby subject to this Agreement; provided, however, that the Purchaser
shall not be required to make any payment pursuant to Section 3 hereof to
acquire any employee stock options that are granted after the Effective Date to
the extent such options are not vested on the date the Exercise Notice is given;
and

            (b) Holder shall not permit any Encumbrances to attach to the Holder
Securities.

         8. Grant of Security Interest. In order to secure the Holder's
obligations hereunder, effective as of the Effective Date, the Holder hereby
pledges and grants to the Purchaser a security interest in all of the Holder
Securities. The Holder shall retain the rights to vote, to transfer (as provided
in Section 12 hereof), to receive dividends on and to exercise or convert any
Holder Security until an Exercise Notice for such Holder Security has been given
hereunder.

         9. Waiver of Rights of First Refusal, etc. Holder hereby waives all
rights to consent, rights of first refusal, rights of first offer, pre-emptive
rights, tag along rights, drag along rights and other rights to acquire Equity
Securities of the Company as such rights in any way relate to (i) the purchase
by the Purchaser of capital stock of the Company pursuant to the Investment
Agreement, (ii) the exercise by the Purchaser of its rights under any of the
other Securities Purchase Agreements or (iii) the exercise of Call Rights (as
defined in the Investment Agreement) by the Company at the direction of the
Purchaser.

         10. Direction to Deliver Shares. The Holder hereby irrevocably directs
the Company, upon the conversion, exercise or exchange of any Equity Securities
into or for Common Stock, to deliver such shares of Common Stock to the
Purchaser to be held in accordance with the terms of this Agreement. The Company
hereby consents to such direction and agrees to deliver any such shares of
Common Stock to the Purchaser upon delivery by the Purchaser of Holder
Securities

                                      -8-

<PAGE>   9

for conversion.

         11. Attorney-in-Fact. The Holder hereby irrevocably constitutes the
Purchaser, and empowers the Purchaser to act, as its attorney-in-fact with
authority to execute, acknowledge and swear to all instruments and file all
documents, including without limitation financing statements on Form UCC-1,
requisite to carrying out the intention and purpose of this Agreement. The power
of attorney granted hereby shall be irrevocable and shall be deemed to be a
power coupled with an interest and shall survive the bankruptcy, death,
incompetence or dissolution of the Holder.

         12. Restrictions on Transfer. The Holder shall not transfer any of the
Holder Securities except to a transferee who executes a counterpart of this
Agreement.

         13. Specific Performance. The Holder acknowledges that damages would be
an inadequate remedy for any breach of the provisions of this Agreement and
agrees that the obligations of the Holder hereunder shall be specifically
enforceable and the Holder shall not take any action to impede the Purchase from
seeking to enforce such right of specific performance.

         14. Notices. All notices, requests, claims, demands and other
communication hereunder shall be in writing and shall be deemed fully delivered
on the date of personal delivery or one business day after it is sent via a
reputable nationwide overnight courier service, or three business days after it
is sent by U.S. registered or certified mail, return receipt requested, postage
prepaid, in each case to the Holder at the address set forth below the Holder's
name on the signature page hereof, and to the Purchaser at: 45 William Street,
Wellesley, MA 02481, attention: Terrance L. Carlson, Esq. and a copy to Hale and
Dorr LLP, 60 State Street, Boston, MA 02109, attention: David E. Redlick, Esq.
and Kenneth A. Hoxsie, Esq., or to such other address as either party may
furnish to the other in writing in accordance herewith.

         15. Successors and Assigns. This Agreement shall inure to the benefit
of and be binding upon the parties hereto and their respective heirs, personal
representatives, successors and assigns.

         16. Assignment of Purchaser. The Purchaser may, without the consent of
the Holder, assign its rights under this Agreement to one or more of its
affiliates, so long as the Purchaser remains primarily liable for its
obligations hereunder.

         17. Governing Laws. This Agreement and the transactions contemplated
herein shall be governed by, and this Agreement shall be construed in accordance
with, the laws (and not the law of conflicts) of the State of Delaware as to all
issues or matters. Each of the parties hereto (a) submits to the jurisdiction of
any state or federal court sitting in Delaware in any action or proceeding
arising out of or relating to this Agreement, (b) agrees that all claims in
respect of the action or proceeding may be heard and determined in any such
court, (c) agrees not to bring any action or proceeding arising out of or
relating to this Agreement in any other court and (d) waives any right it may
have to a trial by jury with respect to any action or proceeding arising out of
or relating to this Agreement. Each of the parties waives any defense of
inconvenient forum to the

                                      -9-
<PAGE>   10

maintenance of any action or proceeding so brought and waives any bond,
surety or other security that might be required of any other party with respect
thereto. Any party hereto may make service on another party hereto by sending or
delivering a copy of the process to the party to be served at the address and in
the manner provided for giving of notices in Section 14. Nothing in this Section
17, however, shall affect the right of any party hereto to serve legal process
in any other manner permitted by law.

         18. Execution in Counterpart. This Agreement may be executed in several
counterparts, each of which shall be an original, but all of which together
shall constitute one and the same agreement.

         19. Severability. The invalidity or unenforceability of any provision
of this Agreement shall not affect the validity or enforceability of any other
provision of this Agreement, which shall remain in full force and effect.

20. Amendment and Waiver. No amendment or waiver of any provision of this
Agreement or consent to departure therefrom shall be effective unless in writing
and signed by the Purchaser and the Holder, in the case of an amendment, or by
the party which is the beneficiary of such provision, in the case of a waiver or
consent to departure therefrom.

         21. Entire Agreement. This Agreement sets forth the entire
understanding of the parties hereto and supersedes all prior agreements,
covenants, arrangements, communications, representations and warranties, whether
oral or written, by either party.

         22. Further Assurances. From time to time, at the Purchaser's request
and without further consideration, the Holder will execute and deliver to the
Purchaser such documents and take such action as the Purchaser may reasonably
request in order to consummate more effectively the transactions contemplated
hereby and to vest in the Purchaser good, valid and marketable title to the
Holder Securities that are purchased by the Purchaser in accordance with the
terms hereof, including, but not limited to, using its best efforts to cause the
Company or its transfer agent to transfer the Holder Securities on the transfer
books of the Company to the Purchaser.

         IN WITNESS WHEREOF, this Agreement has been duly executed by the
parties hereto as of the day and year first above written.

                                   PURCHASER:

                                   PerkinElmer, Inc.

                                   By
                                      ----------------------------------------
                                      Name:
                                      Title:

                                   HOLDER:

                                      -10-
<PAGE>   11

                                        ----------------------------------------

                                        By
                                          --------------------------------------

                                        Address:
                                                --------------------------------
                                        ----------------------------------------

                                      -11-
<PAGE>   12

         Genomic Solutions Inc., hereby
         consents to and agrees to be bound
         by the provisions of Section 10 of
         this Agreement

         By:
            -------------------------------

                                      -12-<PAGE>   1
                                                                    EXHIBIT 10.2

                   SALES, MARKETING AND DISTRIBUTION AGREEMENT

     THIS SALES, MARKETING AND DISTRIBUTION AGREEMENT (the "Agreement") is made
and entered into as of December 14, 1999 (the "Effective Date"), by and between
Genomic Solutions, Inc., a Delaware corporation, and PerkinElmer, Inc., a
Massachusetts corporation.

                                    RECITALS:

     Genomic Solutions, Inc. manufactures and distributes biochip systems,
protemic systems, gel analysis products and other products, software and systems
in the United States and throughout the world.

     Genomic Solutions, Inc. desires to hire PerkinElmer, Inc. to promote,
market and distribute its products and services and perform certain field
service responsibilities, subject to the terms and conditions of this Agreement.

     NOW THEREFORE, for and in consideration of the foregoing Recitals, the
mutual covenants and undertakings set forth below and other good and valuable
consideration, the receipt and adequacy of which are acknowledged, the
undersigned agree as follows:

1.   Definitions. The following terms shall have the meaning set forth in this
     section. All other capitalized terms shall have the meaning set forth in
     the section defining such terms.

     (a)  "Active Date" means January 1, 2000 or such other date as the parties
          shall mutually agree in writing.

     (b)  "Affiliates" of a party shall mean any person, corporation or other
          business entity controlled, controlled by or under common control with
          such party, with "control" meaning a fifty percent (50%) or greater
          ownership interest.

     (c)  "Core Markets" means the United States of America, the United Kingdom
          and Japan.

     (d)  "GSI" means Genomic Solutions, Inc. and its Affiliates.

     (e)  "GSI Products" means the products identified on Exhibit A hereto. In
          the event that during the Term, GSI offers any other products not
          described on Exhibit A, such products shall automatically be deemed
          "GSI Products" for purposes of this Agreement. GSI shall provide PKI
          with thirty (30) days advance written notice of the discontinuation of
          the manufacture of any GSI Product and the material modification or
          improvement of any GSI Product.

     (f)  "PKI" means PerkinElmer, Inc. and its Affiliates

     (g)  "Term" means the two (2) year period commencing on the Active Date,
          provided, that upon expiration of the initial Term, this Agreement
          shall automatically review for successive two (2)

<PAGE>   2

          year periods unless either party notifies the other in writing at
          least ninety (90) days prior to the expiration of the then current
          term of its intention not to renew.

2.   Preparation Activities.

     (a)  Preparation Sales. Commencing on the Effective Date, PKI may begin
          promoting the sale of the GSI Products and will work with GSI to
          prepare for the assumption of certain sales, marketing, distribution
          and field service activities on the Active Date. GSI shall be
          responsible for all sales and distribution activities world-wide prior
          to the Active Date (including all sales, marketing, distribution and
          service costs) and shall be entitled to receive all revenue from such
          activities. GSI shall also be entitled to all world-wide revenue from
          orders for GSI Products placed prior to the Active Date, so long as
          such GSI Products are actually shipped within one hundred eighty (180)
          days after the Active Date.

     (b)  Preparation Activities. Commencing on the Effective Date, GSI and PKI
          shall jointly and cooperatively prepare for PKI's distribution of GSI
          Products outside of Core Markets and promotion of GSI Products in the
          Core Markets as contemplated in Sections 3 and 4, respectively. GSI
          and PKI shall provide sufficient resources commencing on the Effective
          Date to allow PKI to undertake sales and distribution of GSI Products
          on the Active Date. Such preparation activities shall include, but not
          be limited to, the following:

          (i)   Training and preparation of PKI sales and field service forces,
                including account planning, quota setting, role definition and
                other sales preparation activities.

          (ii)  Incorporation of sales and service activities into PKI
                infrastructure, including logistics preparation and planning.

          (iii) Development of coordinated marketing launch and plan, including
                development of integrated message to customers, branding
                preparation and other launch related activities.

3.   Exclusive Distributor Appointment.

     (a)  Exclusive Rights and Responsibilities of PKI. Effective as of the
          Active Date and subject to the terms of this Agreement, PKI shall have
          the exclusive right and responsibility to engage in sales, marketing,
          distribution and field service activities with respect to GSI Products
          in any market or geographical area other than the Core Markets
          provided, however, that: (i) GSI has distributor contracts for
          non-Core Markets with those third parties listed in Exhibit B hereto,
          with territories and termination notice periods as set out in such
          Exhibit B for each such contract; and (ii) GSI shall send all of its
          distributors in the non-Core Markets as listed on Exhibit B notices of
          termination as soon as possible, but no later than four (4) days after
          the first date on which it may send such termination notices, through
          whatever means necessary to ensure that such third parties receive
          those notices as soon as possible (except the parties will work
          together in good faith to allow PKI to utilize Science & Technology,
          Ltd., the current distributor for GSI in New Zealand, from and after
          the Active Date).

<PAGE>   3

     (b)  Sales Goals and Quotas. GSI shall make GSI Products available to PKI
          in accordance with the terms and pricing in Section 7 below. Exhibit C
          attached is a schedule of PKI sales targets for the first four (4)
          quarters after the Active Date. Purchases of GSI Products in excess of
          the minimum sales target set forth in Exhibit C for any calendar
          quarter shall be credited towards the minimum sales target set forth
          therein for subsequent calendar quarters. These minimum sales targets
          are U.S. Dollar volumes based on GSI Product orders received by GSI
          from PKI on or before the last day of such calendar quarter, and are
          based on GSI's transfer price to PKI for such GSI Products. Exhibit C
          shall be reviewed and updated annually by the parties to set new
          quarterly minimum sales targets. In the event that parties are unable
          to agree on sales targets, the matter will be submitted for
          arbitration before a single arbitrator approved by the parties. All
          arbitration shall take place in accordance with the rules of the
          American Arbitration Association at such organization's Wilmington,
          Delaware offices. Such arbitrator shall make such adjustments based on
          then-current market conditions.

     (c)  Failure to Meet Minimum Sales. In the event that PKI fails to meet the
          quarterly minimum sales for GSI Products for three (3) consecutive
          calendar quarters, GSI, in its sole discretion and upon notice to PKI,
          may convert PKI's right to sell, market, distribute and provide field
          services for GSI Products outside of the Core Markets from exclusive
          to non-exclusive.

     (d)  Consideration. The consideration for the grant of exclusivity of
          distribution to PKI in the non-Core Markets shall consist of PKI's
          obligations under this Agreement to sell, market, distribute and
          service the GSI Products and other good and valuable consideration,
          the receipt and adequacy of which are acknowledged.

4.   Non-Exclusive Sales Representative Activities of PKI; PKI Providing
     Technical Assistance Services.

     (a)  Appointment of PKI as Sales Representative. PKI shall promote the
          products within the Core Markets, providing sales leads and opening
          access to PKI's broad network of customer relationships within the
          Core Markets. PKI shall therefore, from time to time after the Active
          Date, identify Leads in the Core Markets and communicate the identity
          of those Leads to GSI. GSI hereby appoints PKI, effective as of the
          Active Date, as a non-exclusive sales representative for the GSI
          Products in Core Markets. GSI further agrees that it will not, without
          first obtaining PKI's written consent (with such consent not to be
          unreasonably withheld) appoint any additional sales representatives,
          dealers, distributors or other agents in connection with the marketing
          and distribution of the GSI Products in the Core Markets after the
          Effective Date; except, however, that GSI may make customary changes
          in the ordinary course of business to its dealer/distributor network
          in Japan without first obtaining PKI's written consent.

     (b)  Sales Commissions. GSI shall pay sales commissions to PKI for sales
          procured as a result of assistance or efforts of PKI as follows:

          (i)   For all sales directly attributable to Leads or assistance
                provided by PKI to GSI, GSI shall pay to PKI a commission based
                on a percentage of the Net Revenue (as defined below) actually
                received by GSI with respect to such sales. The commission for
                any particular sale shall be determined based on the mutual
                agreement of the parties taking into consideration the foregoing
                and the relative contributions to the sale by the parties. For
                purposes of this section, "Lead" means a qualified lead or
                prospect, including name of company, key contact, defined need,
                reasonable indication of finances, and other information to
                indicate that a relationship has been established for a bona
                fide prospective purchaser of GSI Products.

          (ii)  Timing of Payments. All commissions due and payable to PKI shall
                be paid by GSI to PKI within thirty (30) days after the end of
                the calendar quarter in which payment is actually received by
                GSI. Such commissions shall be paid in three separate checks,
                corresponding to the amounts earned in each of the three Core
                Markets.

          (iii) Definition of Net Revenue. For purposes of this Agreement, Net
                Revenue means the invoice amount of sales of GSI Products to end
                users attributable to Leads or assistance provided by PKI,
                excluding fees for personal or field services, software upgrade
                or maintenance services, freight charges, tariffs, taxes or
                similar charges and net of all discounts, returns and
                allowances, for (A) an initial purchase and subsequent purchases
                by an account during the six-month period immediately following
                such initial purchase; and thereafter (B) any subsequent
                purchases by such account, for which PKI sales personnel were
                directly involved in obtaining such purchases.

          (iv)  GSI shall deliver to PKI within forty-five (45) days after the
                end of each calendar quarter, beginning with March 31, 2000, a
                written report describing, for the applicable quarter: (A) GSI's
                Net Revenues subject to the commissions described in this
                Section 4(b); and (B) the Leads who have paid such amounts to
                GSI. Each such report shall be accompanied by full payment to
                PKI of the total commissions due to PKI for such Net Revenues.

          (v)   All commissions payable to PKI hereunder shall be paid in U.S.
                Dollars and there shall be no chargebacks against such
                commissions. To the extent that the Net Revenues upon which such
                commissions are computed are received by GSI in a currency other
                than U.S. Dollars, GSI shall convert such fees into U.S. Dollars
                in accordance with its normal accounting procedures.

          (vi)  In order for PKI to confirm full payment of the commissions due
                to PKI from GSI in accordance with this Section 4(b), GSI agrees
                to make and keep full and accurate books and records in
                sufficient detail to enable commissions payable hereunder to be
                determined. On thirty (30) days' prior written notice to GSI
                (but no more than twice during any calendar year), PKI's
                independent certified public accountants shall have full access
                to the books and records of GSI necessary to confirm the
                commissions which are due to PKI hereunder, and for no other
                purposes, and such accountants shall have the

<PAGE>   4
                right to make copies therefrom at PKI's expense. PKI's
                independent certified public accountants shall have such access
                during normal business hours. Prompt adjustment shall be made by
                the proper party to compensate for any errors or omissions. PKI
                shall pay all costs of conducting audits pursuant to this
                Section 4(b)(vi); provided, however, that GSI shall reimburse
                PKI in full for PKI's reasonable out-of-pocket costs whenever an
                audit reveals that, with respect to any audited period, the
                underpayment of commissions due was greater than ten percent
                (10%) of the commissions actually paid to PKI for such period.
                PKI agrees to hold confidential all information learned in the
                course of any audit of GSI's books and records hereunder, except
                when it is necessary for PKI to reveal such information in order
                to enforce its rights under this Agreement, or except when
                compelled by law.

     (c)  All commissions due and owing to PKI hereunder but not paid by GSI on
          the due date thereof shall bear interest (in U.S. Dollars) at the rate
          of the lesser of: (i) twelve per cent (12%) per annum; and (ii) the
          maximum lawful interest rate permitted under applicable law. Such
          interest shall accrue on the balance of unpaid amounts from time to
          time outstanding from the date on which portions of such amounts
          become due and owing until payment thereof in full.

5.   PKI Obligations Generally.

     (a)  Product Labeling. All GSI Products shall be sold under the GSI name
          and logo which will be the predominant branding element. Both parties
          acknowledge and agree that the presence of PKI's "PerkinElmer" brand
          will facilitate market recognition, credibility and customer
          communications. Accordingly, PKI shall cooperate with GSI to design
          and produce a subordinated brand label for GSI Products distributed
          outside Core Markets (eg. "in partnership with PerkinElmer) and a
          miniature brand label (eg. "Perkin Elmer global alliance partner) for
          use in Core Markets. PE shall bear all of its own costs and expenses
          incurred in connection with such design activity and GSI shall bear
          its own cost in connection with production activities.

     (b)  Inventory and Production Forecasts. PKI shall provide GSI with a six
          month non-binding rolling production forecast of anticipated sales and
          GSI Products requirements. Such forecast shall be updated and
          delivered to GSI on a monthly basis for each of the particular
          countries where PKI will be undertaking sales activities. PKI shall
          also keep GSI reasonably informed of potential problems concerning the
          GSI Products. All shipments shall be made by GSI to PKI facilities or
          warehouses, with PKI (or its distributors) then responsible for
          further distribution to end-users.

     (c)  Marketing, Promotion and Sales Efforts. PKI shall use commercially
          reasonable efforts to market, promote the sale of, maintain and
          service the GSI Products in markets other than Core Markets and to
          market and promote the sale of GSI Products in Core Markets, subject
          to the other provisions of this Agreement. PKI shall provide and
          maintain, at its own expense, suitable facilities with adequate and
          efficient sales personnel and field engineers. PKI shall provide all
          ordinary service to its customers in markets outside the Core Markets
          as the nature of the business makes necessary or desirable in
          connection with the sale and distribution of GSI Products.

<PAGE>   5

     (d)  Promotional Materials. PKI will develop marketing and promotional
          material for generating leads and sales of the GSI Products at its
          sole cost and expense. Such materials shall conform with the labeling
          standards set forth in subsection (a) above and shall be subject to
          the approval of GSI.

     (e)  License to GSI Marks. GSI hereby grants to PKI a nonexclusive,
          royalty-free license during the Term to use GSI's name and any other
          trademarks or service marks associated with the GSI Products
          (collectively, the "GSI Marks") in connection with PKI's performance
          of its rights and obligations under this Agreement and to market and
          sell the GSI Products under such GSI Marks. Such license shall be
          non-transferable, except that PKI shall be entitled to grant its
          dealers and others to which it sells GSI Products a nonexclusive,
          nontransferable license to use such GSI Marks in connection with the
          marketing, promotion and sale of such GSI Products. PKI acknowledges
          that GSI is the sole and exclusive owner of all right, title and
          interest in and to the GSI Marks. At no time, whether during or after
          the term of this Agreement, shall PKI (i) represent, in any manner,
          that it has any right, title or interest whatsoever in or to the GSI
          Marks; (ii) use the GSI Marks in any way other than that expressly
          contemplated in this Agreement; (iii) register or attempt to register
          the GSI Marks or any mark or name similar to the GSI Marks under the
          laws of any jurisdiction; or (iv) cause or allow to be done any act or
          thing which would tend to impair the distinctiveness of the GSI Marks
          or any part of GSI's right, title and interest in the GSI Marks. In
          order to comply with GSI's quality control standards, PKI shall: (x)
          use the GSI Marks in compliance with all relevant laws and
          regulations; (y) accord GSI the right to inspect during normal
          business hours, without prior advance notice, PKI's facilities used in
          connection with efforts to sell the GSI Products in order to confirm
          that PKI's use of such GSI Marks is in compliance with this Section
          5(e); and (z) not modify any of the GSI Marks in any way and not use
          any of the GSI Marks on or in connection with any goods or services
          other than the GSI Products.

     (f)  License to PKI Marks. PKI hereby grants to GSI a nonexclusive,
          royalty-free license during the Term to use PKI's name and any other
          trademarks or service marks of PKI (collectively, the "PKI Marks") in
          connection with affixing co-branded labels to the GSI Products, in
          accordance with the co-branding arrangements contemplated herein. Such
          license shall be non-transferable, except that GSI shall be entitled
          to grant its sales representatives, dealers, distributors and other
          agents to which it sells GSI Products in the Core Markets a
          nonexclusive, nontransferable license to use such PKI Marks in
          connection with the marketing, promotion and sale of such GSI
          Products, subject to their compliance with GSI's obligations under
          this Section 5(f). GSI acknowledges that PKI is the sole and exclusive
          owner of all right, title and interest in and to the PKI Marks. At no
          time, whether during or after the term of this Agreement, shall GSI
          (i) represent, in any manner, that it has any right, title or interest
          whatsoever in or to the PKI Marks; (ii) use the PKI Marks in any way
          other than that expressly contemplated in this Agreement; (iii)
          register or attempt to register the PKI Marks or any mark or name
          similar to the PKI Marks under the laws of any jurisdiction; or (iv)
          cause or allow to be done any act or thing which would tend to impair
          the distinctiveness of the PKI Marks or any part of PKI's right, title
          and interest in the PKI Marks. In order to comply with PKI's quality
          control standards, GSI shall: (x) use the PKI Marks in compliance with
          all relevant laws and regulations; (y) accord PKI the right to inspect
          during normal business hours, without prior advance notice, GSI's
          facilities used in connection labeling the GSI Products in order to
          confirm that GSI's use of such PKI Marks is in

<PAGE>   6

          compliance with this Section 5(f); and (z) not modify any of the PKI
          Marks in any way and not use any of the PKI Marks on or in connection
          with any goods or services other than the GSI Products.

6.   Non-Competition.

     (a)  Reverse Engineering, etc. PKI shall not reverse engineer, redesign or
          disassemble or dismantle any GSI Products, except to the extent
          required to carry out the terms and conditions of this Agreement, in
          the biochip or proteomic area for the purpose of attempting to create
          products potentially competitive with the GSI Products. All such data
          regarding the GSI Products will be considered "confidential" for
          purposes of the Mutual Confidentiality Agreement between PKI and GSI
          of even date herewith. In the event that PKI engages in any activity
          as described in the first sentence of this subsection, then GSI may
          immediately terminate this Agreement.

     (b)  Sales of Competitive Products. In the event that PKI sells, markets or
          distributes, directly or indirectly, any products (other than GSI
          Products) which are competitive with any GSI biochip products (defined
          as any products which print or spot DNA on a glass slide or similar
          substrate) or competitive with any GSI proteomics products (defined as
          gels and mass spec products), then GSI shall have the right to convert
          the exclusive rights granted to PKI under Section 3 above to
          non-exclusive rights, upon giving PKI written notice of such
          conversion.

7.   Acceptance of Orders: Fulfillment; Pricing. The following terms shall
     apply for PKI ordering and sales outside of the Core Markets:

     (a)  Order Placement. PKI shall submit to GSI, its orders for the GSI
          Products in writing at least sixty (60) days before delivery is
          required for hardware, instruments and equipment and thirty (30) days
          before delivery is required for consumables, reagents and gels. All of
          PKI's orders for GSI Products consisting of consumables, reagents and
          gels (but excluding demonstration products) shall be for complete
          lots, the size of which shall be determined by GSI in its reasonable
          discretion. In this regard, GSI shall use reasonable efforts to
          minimize its lot sizes.

     (b)  Order Acceptance and Fulfillment. GSI shall give careful consideration
          to PKI's orders for GSI's Products, but all such orders shall be
          subject to GSI's approval and acceptance. If GSI does not communicate
          its rejection of an order to PKI within seven (7) days after receiving
          such order, then GSI shall be deemed to have accepted such order. GSI
          shall not be liable for any rejection of an order. All rejected orders
          shall be deemed purchased by PKI for the purposes of determining
          whether PKI has met the quarterly minimum sales targets in Exhibit C
          hereto. In the event of a shortage of GSI Products, GSI shall accept
          orders and allocate GSI Products in a reasonable manner so as to
          support PKI as a distributor of GSI Products, and at a minimum, GSI
          shall allocate its manufacturing capability on a unit basis so that
          PKI receives the same percentage of GSI's total output of GSI Products
          as PKI received on average during the most recent six (6) months prior
          to the shortage.

     (c)  Servicing and Certain Revenue. PKI shall be solely responsible for all
          installation, field servicing, maintenance and warranty repair with
          respect to GSI Products distributed by PKI

<PAGE>   7

          outside of Core Markets, provided, that GSI shall provide reasonable
          application and technical support to PKI marketing and sales
          personnel. PKI shall be entitled to receive all revenue generated from
          field servicing and maintenance outside of the Core Markets. Revenue
          from software upgrades and maintenance or subscription services shall
          be split equally by GSI and PKI.

     (d)  GSI Product Pricing. GSI shall sell the GSI Products to PKI at the
          transfer prices set forth on Exhibit A attached. If GSI develops any
          new products which constitute GSI Products at anytime after the Active
          Date, the parties shall negotiate in good faith toward reaching a
          mutual understanding as to the rate at which GSI shall sell such GSI
          Products to PKI. All orders of GSI Products by PKI shall be
          non-cancelable. The parties agree to annually evaluate the pricing of
          GSI with consideration to be given for adjustment based on market
          dynamics, the cost of products and services, and changing consumer
          conditions. In the event that the parties fail to reach agreement on
          product pricing, any price changes shall be subject to arbitration as
          provided in Section 3(b) above.

     (e)  F.O.B. All prices are and shall be, and all deliveries of GSI Products
          shall be made, F.O.B. GSI's U.S. or U.K. shipping dock. Risk of loss
          and title to the GSI Products passes to PKI at such F.O.B. point.

     (f)  Invoicing. All invoices for GSI Products shipped shall be due and
          payable in U.S. Dollars on or before the thirtieth (30th) day after
          the later of (i) the date the invoice is sent by GSI; and (ii) the
          date of shipment. All payments due and owing to GSI hereunder but not
          paid by PKI on the due date thereof shall bear interest (in U.S.
          Dollars) at the rate of the lesser of: (i) twelve per cent (12%) per
          annum; and (ii) the maximum lawful interest rate permitted under
          applicable law. Such interest shall accrue on the balance of unpaid
          amounts from time to time outstanding from the date on which portions
          of such amounts become due and owing until payment thereof in full

     (g)  Taxes. All prices for GSI Products shall be quoted or listed exclusive
          of any federal, state or local sales, use or excise taxes levied on or
          measured by the sale, sales price or use of GSI Products
          (collectively, "Taxes"). Unless PKI is exempted from such Taxes, all
          such prices shall be increased by the amount of the Taxes, if any, to
          which the GSI is subject in connection with the sale of the GSI
          Products.

     (h)  Resale Prices. PKI may sell the GSI Products at such prices and on
          such terms and conditions as it deems appropriate in its sole
          discretion. PKI shall have no authority to obligate GSI in any way
          through the terms and conditions on which it sells the GSI Products.

     (i)  Limited GSI Products Warranty. GSI will warrant all GSI Products
          (parts only) sold outside of Core Markets against defects in materials
          or workmanship for a period of twelve (12) months from the customer
          installation date under normal service and use; except that GKI will
          warrant consumables, gels and reagents for a period of ninety (90)
          days after shipment to the customer. The GSI Warranties shall not
          apply to any GSI Product which is used for a purpose or in a manner
          for which it was not intended, which is defectively or improperly
          installed, which is altered in any way other than in connection with
          its proper installation, or which is subject to misuse, negligence,
          accident or neglect, so as to affect adversely the condition,
          performance or

<PAGE>   8

          value of such GSI Product. GSI's obligations with respect to this
          warranty are limited to the repair and replacement of defective parts
          after GSI's inspection and verification of such defects. Such
          obligations specifically exclude labor costs.

     (j)  Disclaimer of Express and Implied Warranties. THE GSI WARRANTY ABOVE
          IS THE ONLY WARRANTY MADE WITH RESPECT TO THE GSI PRODUCTS OR ANY
          PARTS OR COMPONENTS THEREOF, EXPRESS OR IMPLIED. GSI MAKE NO IMPLIED
          WARRANTIES AND SPECIFICALLY DISCLAIMS ANY WARRANTY THAT ITS PRODUCTS
          ARE MERCHANTABLE OR FIT FOR ANY PARTICULAR PURPOSE.

     (k)  Remedy; Limitation of Liability. If PKI believes that GSI has breached
          any warranty it shall notify GSI of the way in which the GSI Product
          is defective and, upon request, shall return at GSI's expense the
          defective GSI Product or component part to GSI. If GSI agrees that the
          GSI Product is defective, it shall promptly repair or replace the
          defective GSI Product or issue a credit for the price of the GSI
          Product. EXCEPT WITH RESPECT TO THIRD PARTY PRODUCT LIABILITY CLAIMS
          ARISING FROM GSI PRODUCTS NOT CONFORMING TO THIS WARRANTY AND EXCEPT
          FOR GSI'S INDEMNIFICATION OBLIGATIONS UNDER SECTION 8(b)(vi) BELOW, IN
          NO EVENT SHALL EITHER PARTY BE LIABLE TO THE OTHER PARTY OR ANY
          PURCHASER OF GSI PRODUCTS FOR INDIRECT, SPECIAL, INCIDENTAL,
          EXEMPLARY, PUNITIVE OR CONSEQUENTIAL DAMAGES, FOR LOSS OF ANTICIPATED
          PROFITS OR BUSINESS, OR FOR INTERRUPTIONS IN BUSINESS, WITH RESPECT TO
          ANY CLAIM OF ANY KIND RESULTING FROM THE GSI PRODUCTS OR THEIR USE OR
          MISUSE, ANY ORDER UNDER THIS AGREEMENT OR ANY PERFORMANCE,
          NON-PERFORMANCE OR BREACH OF THIS AGREEMENT, WHETHER THE BASIS OF SUCH
          LIABILITY IS BREACH OF CONTRACT, TORT (INCLUDING, WITHOUT LIMITATION,
          NEGLIGENCE AND STRICT LIABILITY), STATUTORY OR ANY OTHER LEGAL THEORY
          WHATSOEVER. The remedy set forth in this Section shall be PKI's sole
          and exclusive remedy for breach of GSI's warranties.

8.   Indemnity.

     (a)  PKI shall defend and hold harmless GSI, its Affiliates and all
          officers, directors, employees and agents thereof against and from any
          and all claims made against GSI based upon, arising out of or in any
          way related to (i) PKI's acts or omissions in connection with the
          sale, marketing, distribution, installation, maintenance and servicing
          of the GSI Products; (ii) PKI's conduct or operation of its business;
          (iii) any negligent acts or omissions of PKI or any of its agents,
          contractors or employees; (iv) any representations or warranties made
          by PKI with respect to the GSI Products which were not authorized by
          GSI; (v) any breach or violation of this Agreement; and (vi) PKI's
          failure to comply with relevant laws and regulations. Such indemnity
          shall extend to all costs, awards, claims or damages of any kind or
          nature, including attorney fees and related expenses ("Damages").

     (b)  GSI hereby agrees to indemnify, defend and hold harmless PKI, its
          Affiliates and all officers, directors, employees and agents thereof
          from all Damages arising out of (i) GSI's acts or omissions in
          connection with the production, sale, marketing, distribution,
          installation, maintenance and servicing of the GSI Products; (ii)
          GSI's conduct or

<PAGE>   9

          operation of its business; (iii) any negligent acts or omissions of
          GSI or any of its agents, contractors or employees; (iv) GSI's breach
          of this Agreement; (v) GSI's failure to comply with relevant laws and
          regulations; and (vi) PKI's use or reselling of the Products
          infringing on the intellectual property rights of third parties or
          constituting a misappropriation of any third party's trade secrets;
          provided, however, that with respect to part (vi) above:

          (A)  In the event that any GSI Product is held in a suit or proceeding
               to infringe any intellectual property rights of a third party and
               the use or reselling of such GSI Product is enjoined, or GSI
               reasonably believes that it is likely to be found to infringe or
               likely to be enjoined, then GSI shall, at its sole cost and
               expense, either (1) procure for PKI the right to continue
               reselling such GSI Product; or (2) modify such GSI Product so
               that it becomes non-infringing. If neither (1) nor (2) is
               practicable, then GSI may, in its sole discretion, cease
               distributing such GSI Product in the affected countries outside
               the Core Markets, in which case such GSI Product shall be deemed
               removed from this Agreement with respect to such affected
               countries upon repurchasing PKI's inventory of such GSI Product
               which are saleable and in the original packages and unaltered
               from their original form and design, subject to GSI's inspection,
               test, and acceptance. Any such repurchase of PKI's inventory of
               GSI Products shall be at the product prices indicated in Exhibit
               A hereto. Such repurchased inventory shall be shipped by PKI,
               freight and insurance to be paid by GSI, according to GSI's
               instructions. GSI shall pay PKI for such repurchased GSI Products
               within thirty (30) days after GSI receives those GSI Products in
               one of its facilities.

          (B)  GSI shall have no obligation for any claim of infringement
               arising from: (1) any combination of GSI Products with products
               not supplied or approved in writing by GSI, where such
               infringement would not have occurred but for such combination;
               (2) the adaptation or modification of GSI Products not approved
               by GSI, where such infringement would not have occurred but for
               such adaptation or modification; (3) the use of a GSI Product in
               an application for which it was not designed, intended or
               approved by GSI, where such infringement would not have occurred
               but for such use; (4) a claim based on intellectual property
               rights owned by PKI or any of its Affiliates; or (5) improper
               service or installation.

     (c)  The party seeking indemnification (be it GSI under Section 8(a) above
          or PKI under Section 8(b) above) (the "Indemnified Party") hereby
          agrees that: (i) the Indemnified Party shall give the other party (the
          "Indemnifying Party") prompt written notice of each such claim; (ii)
          the Indemnifying Party shall have sole control and authority with
          respect to the defense or settlement of any such claim; and (iii) the
          Indemnified Party shall cooperate fully with the Indemnifying Party,
          at the Indemnifying Party's sole cost and expense, in the defense of
          any such claim. Any settlement of any such claim that imposes any
          liability or limitation on the Indemnified Party shall not be entered
          into without the prior written consent of the Indemnified Party.

<PAGE>   10

     (d)  In the event a claim is based partially on an indemnified claim
          described in Sections 8(a) and/or 8(b) above and partially on a
          non-indemnified claim, or is based partially on a claim described in
          Section 8(a) above and partially on a claim described in Section 8(b)
          above, any payments and reasonable attorney fees incurred in
          connection with such claims are to be apportioned between the parties
          in accordance with the degree of cause attributable to each party.

     (e)  During the term of this Agreement, GSI shall maintain an occurrence
          based comprehensive general liability insurance policy issued by a
          reputable insurance company, naming PKI as an additional insured,
          which policy shall insure against any and all bodily injury and/or
          property damages for which GSI has agreed to indemnify PKI as stated
          above in this Section 8. Such insurance shall be in the amount of at
          least $1,000,000 per claim and $2,000,000 for claims in the aggregate.

9.   Assistance.

     (a)  Promotional Materials. GSI shall make available to PKI, such
          advertising, sales and promotional materials, price lists, sales
          assistance and other information concerning the GSI Products as GSI
          deems appropriate in its reasonable discretion. PKI shall not produce
          or cause to be produced any advertising, sales, promotional or other
          information concerning the GSI's Products without GSI's prior review
          and written consent, which shall not be unreasonably withheld or
          delayed. On termination of this Agreement by either party for any
          reason whatsoever, PKI shall immediately return to GSI any and all
          advertising, sales or promotional materials, price lists, copies of
          invoices and any and all other documents, materials or records
          pertaining to the GSI Products, whether produced by or at the
          direction of PKI or GSI.

     (b)  Technical Support and Assistance. GSI agrees to make reasonable
          efforts to answer any technical support inquiries which GSI receives
          from PKI.

10.  Early Termination.

     (a)  Termination by Either Party. Any provision of this Agreement to the
          contrary notwithstanding, either party shall have the right to
          terminate this Agreement, at any time without prior notice, except as
          required below, on the occurrence of any of the following:

          (i)   The other party fails, neglect or refuses in any material manner
                to satisfactorily perform the duties assigned to or required of
                it under this Agreement, but only after such other party has
                been given sixty (60) days notice of and opportunity to cure
                such failure, neglect or refusal;

          (ii)  The other party becomes insolvent or unable to pay its debts as
                they become due or makes an assignment for the benefit of its
                creditors;

          (iii) A receiver or a trustee is appointed for the other party's
                assets, and such receiver or trustee is not discharged within
                sixty (60) days of such appointment;
<PAGE>   11

          (iv)  A proceeding of any nature under the federal Bankruptcy Code, as
                amended, or any state insolvency statute, is commenced by or
                against the other party, and such proceeding, if involuntary, is
                not set aside within sixty (60) days from the date of its
                institution;

          (v)   Either party shall have the right to terminate this Agreement
                with ninety (90) days written notice given no later than sixty
                (60) days after the occurrence of the following two conditions:
                (A) the consummation of a bona fide initial public offering of
                GSI's capital stock that is firmly underwritten by a nationally
                recognized underwriter, that results in no less than $20,000,000
                of gross proceeds to GSI and that results in GSI's stock being
                listed for trading on the New York Stock Exchange or the
                National Market Tier of the Nasdaq Stock Market (defined herein
                as "IPO"), and (B) a post-IPO "change in control" of GSI,
                defined as the sale of all or substantially all of the business
                and assets of GSI or a sale of more than 50% of the issued and
                outstanding shares of GSI. The parties further agree that the
                foregoing right of termination shall not apply (X) merely
                because an IPO has occurred, or to an event that may be
                considered a change of control in GSI but does not follow an
                IPO, including by way of example, (Y) the sale of all or
                substantially all of the business and assets of GSI prior to an
                IPO or (Z) a sale of more than 50% of the issued and outstanding
                shares of GSI prior to an IPO.

     (b)  Termination by GSI. In addition to the foregoing, GSI may terminate
          this Agreement in the event that PE fails to make any required
          payments on the due date thereof and such failure is not cured within
          fifteen (15) days of notice by GSI to the addresses indicated in
          Section 14 below.

     (c)  Effect of Termination or Expiration. Upon termination or expiration of
          this Agreement, as the case may be, PKI shall have no right to market
          and distribute the GSI Products (except for the six-month period
          immediately following the effective date of termination or expiration,
          as the case may be, during which PKI shall be entitled to sell-off its
          inventory of GSI Products) and all licenses hereunder shall
          immediately terminate. PKI shall not be entitled to any commissions
          for sales closed after termination or expiration, regardless of
          whether PKI participated in the sale. In addition, each party shall
          return to the other party all copies of any promotional material,
          written literature, product samples, and any Confidential Information
          as herein defined. Termination and expiration shall not affect PKI's
          obligations with respect to GSI Products previously sold hereunder or
          with respect to any indebtedness owed by either party to the other.

     11.  RESERVED

12.  Dealer Status. Nothing in this Agreement shall be construed in such a
     manner as to constitute one party the agent or legal representative of the
     other party for any purpose whatsoever. Neither party shall have any
     authority whatsoever, whether express or implied, to assume, create or
     incur any obligation or liability whatsoever on behalf of or in the name of
     the other party, or to bind the other party in any manner whatsoever.
     Neither party shall be liable for any damages, loss, cost or expense
     whatsoever, including incidental or consequential damages, resulting from
     any sale or other activities performed by the other party.

<PAGE>   12

13.  Cooperative Exchange and Licensing. Attached as Exhibit D hereto is a list
     of representative PKI technologies. PKI agrees to license GSI, on a
     non-exclusive basis, the right to use those technologies to make, use and
     sell products for the proteomic market and/or for the biochip market. As
     GSI identifies each such use of those PKI technologies, the license fee
     level for such use will be set by the parties at then-current market rates,
     based upon the specific technology to be licensed and the intended use. GSI
     will receive a 30% discount on the agreed-upon license fees so long as: (i)
     this Agreement remains in effect; and (ii) PKI's rights under Section 3
     above remain exclusive. If either of these conditions (i) or (ii) is not
     met, then GSI will lose the 30% discount, but will maintain the license
     rights at the agreed-upon market rates. At the time the parties set the
     license fee level for each such use, they shall also negotiate in good
     faith to conclude the other terms and conditions of such license agreement.

14.  Notices. Any and all notices, requests, demands and other communications
     permitted under or required pursuant to this Agreement (each, a "notice")
     shall be in writing and shall be (i) personally delivered; (ii) sent by
     facsimile transmission (with a hard copy to follow in one of the other
     manners contemplated in this Section 14); (iii) sent via overnight courier,
     shipping charges prepaid; or (iv) sent via U.S. Mail, postage prepaid,
     certified mail, return receipt requested, to the parties at the addresses
     or fax numbers set forth below, or at such other addresses or fax numbers
     as they may indicate by written notice given as provided in this Section
     14.

         If to PKI:                           With a required copy to:

         PerkinElmer, Inc.
         45 William Street                    Hale and Dorr LLP
         Wellesley, Massachusetts  02481      60 State Street
                                              Boston, Massachusetts  02109
         Fax no: 781-431-4115                 Fax no.:  617-526-5000
         Attn: General Counsel                Attention:  David E. Redlick

         If to GSI:                           With a required copy to:

         Genomic Solutions Inc.               Jaffe, Raitt, Heur & Weiss,
         4355 Varsity Drive                   Professional Corporation
         Ann Arbor, MI  48108                 One Woodward Avenue, Suite 2400
         Fax:  (734) 975-4808                 Detroit, MI  48226
         Attn:  Jeff Williams                 Fax:  (313) 961-8358
                                              Attention:  Peter Sugar

     Any notice sent in the manner contemplated in clause (i) above shall be
     deemed to have been given on the date delivered; in the manner contemplated
     in clause (ii) above, as of the time the sender receives confirmation from
     its fax machine that the facsimile transmission has been successfully
     completed (provided, however, that if such time is after 4:00 p.m.,
     measured in terms of the recipient's local time, the notice shall be deemed
     to have been given as of 8:00 a.m. on the next business day of the
     recipient); in the manner contemplated in clause (iii) above, on the first
     (1st) business day after the notice has been deposited in a regularly-
     maintained receptacle for such a parcel; and in the manner contemplated in

<PAGE>   13
     clause (iv) above, on the third (3rd) business after the notice has been
     deposited in a regularly-maintained receptacle for U.S. Mail.

     Each party agrees that any press releases, publicity or advertising which
     shall be released by it in which the other party is identified shall
     require the prior written approval of such other party, such approval not
     to be unreasonably withheld or delayed.

15.  Non-Assignable. Neither party may assign this Agreement or its rights or
     obligations under this Agreement without the written consent of the other
     party; which consent may be granted or withheld in the other party's sole
     discretion.

16.  Waiver. Any party's waiver of any breach of any provision of this
     Agreement, and any party's failure to exercise any of its rights under or
     in connection with this Agreement, shall not operate or be construed as a
     waiver by such party of any subsequent or similar breach or of any such
     rights or preclude exercise of such rights at a later time.

17.  Choice of Law: Construction. This Agreement is deemed to have been executed
     in the State of Delaware and shall be construed and enforced in accordance
     with the laws of the State of Delaware, without regard to its conflict of
     laws principles. This Agreement shall not be construed against or in favor
     of any party by virtue of the fact that this Agreement was drafted
     primarily by any one party.

18.  Submission to Jurisdiction. The parties irrevocably submit to the
     jurisdiction of the federal and state courts of Wilmington, Delaware;
     provided, however, that nothing herein shall preclude -------- -------
     either party, if it thinks fit, from instituting proceedings against the
     other party or anyone acting by, through or under the other party in any
     place which may have jurisdiction for the purpose of protecting and
     enforcing such Party's rights either hereunder or pursuant to any other
     agreements, documents, instruments or otherwise. Each party hereby
     irrevocably waives any objection which it may now or hereafter have to the
     laying of venue of any suit, action or proceeding relating to this
     Agreement in Wilmington, Delaware, and further irrevocably waives any claim
     that Wilmington, Delaware is not a convenient forum for any such suit,
     action or proceeding.

19.  Remedies. Any remedy provided in this Agreement for a breach of a specific
     section of this Agreement shall be the sole and exclusive remedy for the
     breach to which it relates. Subject to the preceding sentence, the parties'
     respective rights and remedies under or with respect to breaches of this
     Agreement which are not specifically provided for in this Agreement are
     separate and cumulative, and no one of them, whether or not exercised,
     shall be deemed to be an exclusion of any of the others and shall not limit
     or prejudice any other legal or equitable right which any party to this
     Agreement may have.

20.  Entire Agreement; Amendment. This Agreement represents the complete and
     final expression of the parties' agreements and understandings with respect
     to its subject matter. This Agreement supersedes all other prior oral and
     written agreements between the parties with respect to the subject matter
     of this Agreement. Except to the extent expressly provided in this
     Agreement, this Agreement may not be amended or modified except pursuant to
     a written agreement executed by both parties.

<PAGE>   14

21.  Binding Effect. This Agreement shall be binding on an inure to the benefit
     of the parties and their respective successors and permitted assigns.

22.  Headings. The headings contained in this Agreement are for reference
     purposes only and shall not in any way affect the meaning or interpretation
     of this Agreement.

23.  No Third-Party Beneficiaries. This Agreement, and the respective
     obligations of PKI and GSI under this Agreement, are for the sole and
     exclusive benefit the parties to this Agreement. Any provision of this
     Agreement to the contrary notwithstanding, no party other than PKI, GSI and
     their respective successors and permitted assigns shall have the right to
     rely on or enforce the provisions of this Agreement as a third-party
     beneficiary or otherwise.

24.  Offset. Each party shall be entitled to offset any amounts due it by the
     other party against any amounts which it owes the other party.

25.  Pronouns. References to a party in the singular or plural, as him, her, it
     or other like preferences, shall also, where the context so requires, be
     deemed to include the singular or the plural, or masculine, feminine or
     neuter reference, as the case may be.

26.  Counterparts; Facsimile Signatures. This Agreement may be executed in
     counterparts, each of which shall be deemed an original and all of which
     together shall constitute one instrument. Facsimile or photostatic copies
     of signatures to this Agreement shall be deemed to be originals and may be
     relied on to the same extent as the originals.

27.  Severability. If any provision of this Agreement is declared invalid or
     unenforceable by a court having competent jurisdiction, it is mutually
     agreed that this Agreement shall endure except for the part declared
     invalid or unenforceable by order of such court. The parties shall consult
     and use their best efforts to agree upon a valid and enforceable provision
     which shall be a reasonable substitute for such invalid or unenforceable
     provision in light of the intent of this Agreement

     IN WITNESS WHEREOF, the undersigned have executed and delivered this Sales,
Marketing and Distribution Agreement as of December 14, 1999.

                             Genomic Solutions, Inc.

                             By: Jeffrey S. Williams
                                -----------------------------------
                             Its: President & CEO
                                 ----------------------------------
                             PerkinElmer, Inc.

                             By: Terrance Carlson
                                -----------------------------------
                             Its: SR V.P.
                                 ----------------------------------

<PAGE>   15

                                    EXHIBIT A

                                  GSI PRODUCTS

                          LIST PRICE AND TRANSFER PRICE

<TABLE>
<CAPTION>
------- ----------------------- ----------------------------------------------------------------
        CATEGORY                PRODUCT                                         GSI       PKI
                                                                                LIST   TRANSFER
                                                                               PRICE     PRICE
<S>     <C>                     <C>                                           <C>      <C>
------- ----------------------- ----------------------------------------------------------------

1       BioChip Systems         GeneTAC 2000                                  $ 80,000
------- ----------------------- ------------------------------------------------------
2       BioChip Systems         GeneTAC 3000                                  $ 99,000
------- ----------------------- ------------------------------------------------------
3       BioChip Systems         Flexys Gridding System                        $ 80,000
------- ----------------------- ------------------------------------------------------
4       BioChip Systems         Flexys Gridding with Autoloader               $150,000
------- ----------------------- ------------------------------------------------------
5       BioChip Systems         Flexys Picking System                         $ 90,000
------- ----------------------- ------------------------------------------------------
6       BioChip Systems         Flexys Picking with Autoloader                $160,000
------- ----------------------- ------------------------------------------------------
7       BioChip Systems         Flexys High Density Arraying                  $ 80,000
------- ----------------------- ------------------------------------------------------
8       BioChip Systems         Flexys High Density Arraying with Autoloader  $150,000
------- ----------------------- ------------------------------------------------------
9       BioChip Systems         Hybridization Station 12 Slide                $ 59,000
------- ----------------------- ------------------------------------------------------
10      Proteomic Systems       2-D Electrophoresis System                    $ 13,700
------- ----------------------- ------------------------------------------------------
11      Proteomic Systems       Gel Processor                                 $ 29,000
------- ----------------------- ------------------------------------------------------
12      Proteomic Systems       Proteomic Analyzer System (Darkroom)          $ 55,000
------- ----------------------- ------------------------------------------------------
13      Proteomic Systems       Proteomic Software only                       $ 25,000
------- ----------------------- ------------------------------------------------------
14      Proteomic Systems       Proteomic Analyzer System (Scanner)           $ 30,000
------- ----------------------- ------------------------------------------------------
15      Proteomic Systems       ProGest                                       $ 65,000
------- ----------------------- ------------------------------------------------------
16      Proteomic Systems       ProMS                                         $ 55,000
------- ----------------------- ------------------------------------------------------
17      Proteomic Systems       Flexys Proteomics system (Protein Picker)     $127,000
------- ----------------------- ------------------------------------------------------
18      Proteomic Systems       Maldi Mass Spec                               $265,000
------- ----------------------- ------------------------------------------------------
19      Gel Analysis            GelPrint 2000i                                $ 13,500
------- ----------------------- ------------------------------------------------------
</TABLE>

NOTE:    Destination shipping charges are not included.
         Shipping terms:  FOB GSI's U.S. or U.K. shipping dock.

                                      -16-

<PAGE>   16

                                    EXHIBIT B

                     GENOMIC SOLUTIONS' DISTRIBUTOR SCHEDULE

<TABLE>
<CAPTION>
-----------------------------------------------------------------------------------------------------------------------------
      DATE OF AGREEMENT            AGREEMENT WITH                    TERMINATION ASSUMING DEFINITIVE       COUNTRY
                                                                     AGREEMENT SIGNED DEC. 15, 1999
<S>                           <C>                                    <C>                              <C>
-----------------------------------------------------------------------------------------------------------------------------
          12/15/98            Science & Technology Ltd.              December 15, 2000*               New Zealand
-----------------------------------------------------------------------------------------------------------------------------
           2/15/99            Bio/Can Scientific                     January 14, 2000                 Canada
-----------------------------------------------------------------------------------------------------------------------------
           12/7/98            B&L                                    March 15, 2000                   Benelux
-----------------------------------------------------------------------------------------------------------------------------
           5/26/99            Proteigene SARL                        March 15, 2000                   France
-----------------------------------------------------------------------------------------------------------------------------
           3/16/99            Biogenet                               March 16, 2000                   Poland
-----------------------------------------------------------------------------------------------------------------------------
           3/31/99            Seoulin Scientific Co., Ltd.           March 31, 2000                   South Korea
-----------------------------------------------------------------------------------------------------------------------------
           3/26/99            AbiMed                                 June 15, 2000                    Germany
-----------------------------------------------------------------------------------------------------------------------------
           8/30/99            Sinc Do Brasil Inst.Cientifica         August 30, 2000                  Brazil
-----------------------------------------------------------------------------------------------------------------------------
           9/18/99            Labmate (Asia) PVT. LTD                September 22, 2000               India
-----------------------------------------------------------------------------------------------------------------------------
          11/16/98            Australian Laboratory Services         November 16, 2000                Australia
-----------------------------------------------------------------------------------------------------------------------------
           12/3/98            Feng Jih                               December 3, 2000                 Taiwan and China
-----------------------------------------------------------------------------------------------------------------------------
              ?               Bio Tech A.S.                          March 15, 2000**                 Czech Republic
-----------------------------------------------------------------------------------------------------------------------------
           12/3/98            Feng Jih                               December 3, 2000                 Taiwan and China
-----------------------------------------------------------------------------------------------------------------------------
</TABLE>

*CURRENT PKI DISTRIBUTOR
**NO CONTRACT CAN BE LOCATED.  GSI BELIEVES IT CAN CANCEL THIS AGREEMENT WITH
  90 DAYS NOTICE.

<PAGE>   17

                                    EXHIBIT C

                                PKI SALES TARGETS

<TABLE>
<CAPTION>

Calendar Quarter                     MINIMUM
----------------                     -------
<S>                                 <C>
Q1, 2000
Q2, 2000
Q3, 2000
Q4, 2000
</TABLE>

Note:  These minimums are dollar volume of sales based on orders received by GSI
from PKI and are at GSI's transfer price to PKI.

<PAGE>   18

                                    EXHIBIT D

                                PKI TECHNOLOGIES

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00003-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00003-of-00352.parquet"}]]